Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 2 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00507767Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerTreatment